Business Trends– category –
-
LNP-Delivered Gene Editing Platform Targets Hepatic Lipid Metabolic Disorders for Durable, Single-Intervention Correction
Ace Therapeutics USA Overview This platform focuses on lipid nanoparticle (LNP)-delivered gene editing for heritable lipid disorders, aiming for durable, single-intervention correction of disease-driving genes in the liver. It integrates... -
RNA Therapeutics Advance with Delivery Challenges: mRNA Vaccines, siRNAs, and ASOs Drive Disease Treatment
Facebook (Ambry Genetics) USA Overview Recent publications highlight the profound impact of RNA-based therapeutic modalities, including mRNA vaccines, siRNAs, and ASOs, in treating viral infections, genetic disorders, and cancer. However... -
Pathos AI Licenses Alphamab’s First-in-Class TROP2/HER3 Bispecific ADC JSKN016 in $2.25 Billion Deal to Advance Breast Cancer Treatment
Fierce Biotech USA Overview Pathos AI has licensed JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) from Alphamab, in a deal worth up to $2.25 billion ($125 million upfront, $2.1 billion in milestones). JSKN0... -
Revolutionizing TNBC Treatment: Datroway ADC Gains EU Nod for Immunotherapy-Ineligible Patients
Precision Medicine Online European Union Overview AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has received European Commission approval as a first-line monotherapy for patients with ... -
Comprehensive Guide to Lipid Nanoparticles (LNPs): Key to mRNA Vaccine Success and Future RNA Therapeutic Delivery
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) are crucial nanodrug delivery systems for nucleic acids like mRNA and siRNA, vital for mRNA vaccine success and RNA therapeutics. This guide details LNP composition (ionizable l... -
MDPI Accelerates Non-Coding RNA Cancer Therapy with Organ-Selective LNPs: Achieving Precise Delivery to Liver, Spleen, and Lung
MDPI Switzerland Overview Non-coding RNA (ncRNA) therapeutics in cancer are advancing, with their efficacy significantly influenced by lipid nanoparticle (LNP) characteristics like lipid composition, particle size, and surface charge. Re... -
ACE Therapeutics’ LNP Gene Editing Platform Achieves Over 90% Hepatocyte Selectivity for Lipoprotein-Targeted Cardiovascular Therapeutics
ACE Therapeutics USA Overview ACE Therapeutics' LNP-delivered gene editing platform achieves over 90% efficient hepatocyte-selective delivery for lipoprotein-targeted cardiovascular therapeutics, minimizing extrahepatic editing risks. Th... -
AAV Vector Manufacturing Achieves Kilo-Scale Production with 2,000L+ Suspension Bioreactors, Solving Gene Therapy Bottleneck
Drug Discovery News USA Overview AAV upstream production has achieved significant scalability, with suspension bioreactors reaching over 2,000 liters using adapted HEK293 cells, providing volumetric capacity for clinical and commercial g... -
Mannosylated Spleen-Targeted LNP (LNP-PAM) Enhances mRNA Delivery to Antigen-Presenting Cells, Overcoming Liver Tropism
ACS Publications USA Overview A novel mannosylated spleen-targeted lipid nanoparticle (LNP-PAM) has been developed to significantly enhance mRNA delivery to antigen-presenting cells by integrating active and endogenous targeting. This sy... -
Montara Therapeutics Reimagines Blood-Brain Barrier as Solution, Not Problem, Secures $1M for Brain-Selective mTOR Therapy
Drug Discovery News USA Overview Montara Therapeutics is pioneering an approach to blood-brain barrier (BBB) drug delivery by leveraging the BBB to its advantage for brain-selective pharmacology. Instead of forcing drugs across, their te...
